Multiple myeloma
Nature Reviews Disease Primers · 27.06.2024 · 10 (1)
DOI: 10.1038/s41572-024-00529-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nature Reviews Disease Primers, online erschienen am 27.06.2024. Verfasst von Florent Malard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoin…. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 374-mal zitiert (Crossref) und nennt 287 Literaturangaben.
Abstract (Originalsprache)
Multiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence. It remains incurable because most patients relapse or become refractory to treatments. MM is a genetically complex disease with high heterogeneity that develops as a multistep process, involving acquisition of genetic alterations in the tumour cells and changes in the bone marrow microenvironment. Symptomatic MM is diagnosed using the International Myeloma Working Group criteria as a bone marrow infiltration of ≥10% clonal plasma cells, and the presence of at least one myeloma-defining event, either standard CRAB features (hypercalcaemia, renal failure, anaemia and/or lytic bone lesions) or biomarkers of imminent organ damage. Younger and fit patients are considered eligible for transplant. They receive an induction, followed by consolidation with high-dose melphalan and autologous haematopoietic cell transplantation, and maintenance therapy. In older adults (ineligible for transplant), the combination of daratumumab, lenalidomide and dexamethasone is the preferred option. If relapse occurs and requires further therapy, the choice of therapy will be based on previous treatment and response and now includes immunotherapies, such as bi-specific monoclonal antibodies and chimeric antigen receptor T cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France. florent.malard@inserm.fr.
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.
- Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
- Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
- Department of Hematology, Clinica São Germano, São Paulo, Brazil.
- Department of Hematology, Lille University Hospital and INSERM UMR-S1277 and CNRS UMR9020, Lille, France.
Zitieren
APA
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024). Multiple myeloma. Nature Reviews Disease Primers, 10(1). https://doi.org/10.1038/s41572-024-00529-7
Vancouver
Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nature Reviews Disease Primers. 2024;10(1). doi:10.1038/s41572-024-00529-7
BibTeX
@article{Malard2024,
author = {Malard, Florent and Neri, Paola and Bahlis, Nizar J and Terpos, Evangelos and Moukalled, Nour and Hungria, Vania T M and Manier, Salomon and Mohty, Mohamad},
title = {Multiple myeloma},
journal = {Nature Reviews Disease Primers},
year = {2024},
volume = {10},
number = {1},
doi = {10.1038/s41572-024-00529-7}
}
EUVIMED